Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + SUBA-itraconazole
- Development stage
- Phase 2
- Lead developer
- St Vincent's Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hydroxychloroquine + SUBA-itraconazole is a combination therapy being investigated by St Vincent's Hospital, Sydney, primarily in the HITMAN-PC Phase I/II clinical trial (NCT03513211). This regimen is designed for men with biochemically recurrent (BCR) prostate cancer to delay the initiation of androgen deprivation therapy (ADT). Hydroxychloroquine, a 4-aminoquinoline, acts as an autophagy inhibitor by increasing lysosomal pH and preventing the fusion of autophagosomes with lysosomes. SUBA-itraconazole is a proprietary 'Super BioAvailability' formulation of the antifungal itraconazole, which exhibits multi-modal anti-cancer activity, including inhibition of the Hedgehog signaling pathway via Smoothened (SMO) antagonism, inhibition of angiogenesis via VEGFR2, and disruption of cholesterol trafficking through the NPC1 transporter. Together, the combination targets lysosomal homeostasis and cellular survival pathways that are often upregulated in advanced prostate cancer.
- Other names
- HQ + SIhydroxychloroquine and itraconazole
02
Targets
NPC1 (Niemann-Pick C1 protein binding inhibition)VDAC1 (Hexokinase 2–voltage-dependent anion channel 1 complex)NeuraminidaseSMO (Smoothened)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on hydroxychloroquine + SUBA-itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + SUBA-itraconazole.